©DANIEL ROUSSELOT/Sanofi

Sanofi and Regeneron Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

Originally published on sanofi.com.

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).

Minor positive trends were observed in the primary pre-specified analysis group (critical patients on Kevzara 400 mg who were mechanically ventilated at baseline) that did not reach statistical significance and these were countered by negative trends in a subgroup of critical patients who were not mechanically ventilated at baseline1. In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients were multi organ dysfunction syndrome (6% Kevzara, 5% placebo) and hypotension (4% Kevzara, 3% placebo).

Based on the results, the U.S.-based trial has been stopped, including in a second cohort of patients who received a higher dose of Kevzara (800 mg). Detailed results will be submitted to a peer-reviewed publication later this year.

The primary analysis group included 194 patients who were critically ill with COVID-19 and receiving mechanical ventilation at the time of enrolment. The primary endpoint assessed the percentage of patients who achieved at least a 1-point change from baseline on a 7-point scale, which consisted of 1) death; 2) hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4) hospitalized, requiring supplemental oxygen; 5) hospitalized, not requiring supplemental oxygen – requiring ongoing medical care (COVID-19 related or otherwise); 6) hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care; 7) discharged from hospital. A second cohort, which was partially recruited (n=27), compared Kevzara 800 mg versus placebo.

The Kevzara trial was designed after a small (n=21), single-arm study in China (Xu et al) among mostly severe, febrile hospitalized COVID-19 patients found elevated IL-6 levels and suggested that inhibiting this pathway with the IL-6 blocker tocilizumab rapidly reduced fever and improved oxygenation in severe patients, allowing for successful hospital discharge. The Phase 3 Kevzara trial was designed to evaluate this hypothesis in a large, placebo-controlled trial. The trial has been funded in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under OT number: HHSO100201700020C.

A separate Sanofi-led trial outside of the U.S. in hospitalized patients with severe and critical COVID-19 using a different dosing regimen is ongoing. The same Independent Data Monitoring Committee (IDMC) is overseeing both the Regeneron-led U.S. trial and the Sanofi-led trial outside of U.S., which has recommended that the trial outside of the U.S. continue. The companies expect to report results in Q3 2020.

1: Endpoints  that showed positive trends in patients on mechanical ventilation at baseline, and were countered by negative trends in patients who were not mechanically ventilated at baseline included: the proportion of patients with a 1-point improvement on day 22 (primary endpoint for mechanical ventilation group); the proportion of patients who died by day 29; and proportion of patients who recovered by day 22.

Latest News

Student distressed

25 Percent of American Students Lack Resources for Remote Learning; Is the Death Penalty Inherently Racist?; and More

Digital divide for rural students and students of color continues to worsen. A staggering 25% of all school-aged children in the U.S. live in households without reliable Wi-Fi and consistent broadband internet service or access to web-enabled devices such as a computer or tablet, according to data from the National…

Cox Business and Henderson, Nevada Launch Energy Efficient Smart Lighting Project

Originally published on Cox.com Cox2M IoT Business Line of Cox Communications will Pilot New Lighting Controls The City of Henderson and Cox Communications have successfully deployed the first stage of their smart community collaboration, starting with energy efficient lighting management and controls. Cox2M, the IoT business line of Cox Communications, and the…

Diverse hads unite

More Work Needed For Corporate Diversity Programs; Fourteen Disability Groups Unite to Promote Voting; and More

Corporate diversity efforts still have a long way to go, new report finds. In a report conducted by the research firm Clutch, nearly half of employees surveyed said their company isn’t committed to creating a more diverse workplace and hasn’t successfully improved diversity within the last year. Researchers with Clutch…

San Francisco's Golden Gate Bridge

San Francisco Declares War on Racism; People 55 and Older Face Historic Levels of Unemployment; and More.

San Francisco begins a citywide war on racism and discrimination. Known as the birthplace of the “Summer of Love” and the counterculture movement of the 1960s, San Francisco has long stood as a bastion of individuality and inclusion. And now the city is continuing that fight with the launch of…

portrait of Abraham Lincoln

Was Abraham Lincoln a Racist?

Former Vice President Joe Biden’s mention of Abraham Lincoln’s name during the third presidential debate on Thursday, Oct. 22, was one of the most memorable exchanges in the final presidential debate of 2020. It also caused Lincoln to become a trending topic over much of social media in the hours…